Four cardiovascular outcomes trials (CVOTs) of DPP-4 inhibitors in T2DM patients represented that DPP-4 inhibitors (saxagliptin, alogliptin, sitagliptin, and linagliptin) had no statistically significant impact on cancer incidence, yet some trends of increased incidence of certain cancers are described (Table 3) [96,97,98,99,100]. Here, DPP4 is linked to type 2 diabetes mellitus.